防晒OTC专论GRASE活性成分解读与2026 Bemotrizinol新规
2026年FDA将Bemotrizinol纳入OTC防晒专论,叠加CARES Act行政命令框架,防晒剂合规迎来新变化。目前仅氧化锌与二氧化钛被认定为GRASE安全成分,其余化学防晒剂因数据不足需重新评估。出口企业须按21 CFR 352专论调整配方与标签,避免上市后被扣留。
美国FDA、OTC、NDC化妆品申报认证行业资讯,助力企业合规出海
2026年FDA将Bemotrizinol纳入OTC防晒专论,叠加CARES Act行政命令框架,防晒剂合规迎来新变化。目前仅氧化锌与二氧化钛被认定为GRASE安全成分,其余化学防晒剂因数据不足需重新评估。出口企业须按21 CFR 352专论调整配方与标签,避免上市后被扣留。
21 CFR Part 331 -- Antacid Products for Over-the-Counter (OTC) Human UsePART 331—ANTACID PRODUCTS FOR OVER-THE-COUNTER (OTC) HUMAN USEAuthority:21 U.S.C. 321, 351, 352, 353, 355, 360, 371.Source:39 FR 19874, June 4, 1974, unless otherwise noted.Subpa
21 CFR Part 333 Subpart B - First Aid Antibiotic Drug ProductsSubpart B—First Aid Antibiotic Drug Products§ 333.101 Scope.(a) An over-the-counter first aid antibiotic drug product in a form suitable for topical administration is generally recognized
21 CFR Part 347 - Skin Protectant Drug Products for Over-the-Counter Human UsePART 347—SKIN PROTECTANT DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USEAuthority:21 U.S.C. 321, 351, 352, 353, 355, 360, 371.Source:58 FR 54462, Oct. 21, 1993, unless otherwi
21 CFR Part 350 - Antiperspirant Drug Products for Over-the-Counter Human UsePART 350—ANTIPERSPIRANT DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USEAuthority:21 U.S.C. 321, 351, 352, 353, 355, 360, 371.Source:68 FR 34291, June 9, 2003, unless otherwise
21 CFR Part 352 - Sunscreen Drug Products for Over-the-Counter Human Use [Stayed Indefinitely]PART 352—SUNSCREEN DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE [STAYED INDEFINITELY]Authority:21 U.S.C. 321, 351, 352, 353, 355, 360, 371.Source:64 FR 2768
21 CFR Part 355 - Anticaries Drug Products for Over-the-Counter Human UsePART 355—ANTICARIES DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USEAuthority:21 U.S.C. 321, 351, 352, 353, 355, 360, 371.Source:60 FR 52507, Oct. 6, 1995, unless otherwise noted.Ed
21 CFR Part 358 - Miscellaneous External Drug Products for Over-the-Counter Human UsePART 358—MISCELLANEOUS EXTERNAL DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USEAuthority:21 U.S.C. 321, 351, 352, 353, 355, 360, 371.Source:55 FR 33255, Aug. 14, 1990,
21 CFR Part 358 Subpart D—Ingrown Toenail Relief Drug ProductsSubpart D—Ingrown Toenail Relief Drug ProductsSource:68 FR 24348, May 7, 2003, unless otherwise noted.§ 358.301 Scope.(a) An over-the-counter ingrown toenail relief drug product in a form
2026年FDA OTC专论M020要求防晒产品完成SPF、Broad Spectrum广谱及防水测试,现行16种活性成分各有上限且组合受限。2026年8月9日将增加bemotrizinol 6%,附带18个月法定独占期。中国防晒产品出口美国须按药品cGMP生产,完成FDA注册与NDC列名,专论外成分或组合需另评估NDA路径。